identifi
safe
effect
medic
countermeasur
eg
antiviralsantibodi
address
current
outbreak
novel
coronaviru
method
comprehens
literatur
search
develop
experienc
librarian
medlin
embas
cochran
librari
biorxivorgmedrxivorg
addit
search
ongo
trial
unpublish
studi
conduct
clinicaltrialsgov
global
infecti
diseas
epidemiolog
network
gideon
titleabstract
fulltext
screen
data
abstract
risk
bia
apprais
carri
singl
review
result
studi
includ
review
three
control
trial
cohort
studi
seven
retrospect
medic
recorddatabas
studi
case
report
seri
studi
includ
patient
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
unspecifi
coronaviru
common
treatment
ribavirin
follow
oseltamivir
combin
lopinavirritonavir
addit
therapi
includ
broad
spectrum
antibiot
steroid
variou
interferon
elig
studi
examin
monoclon
antibodi
identifi
one
trial
found
ribavirin
prophylact
treatment
statist
significantli
reduc
risk
mer
infect
peopl
expos
viru
studi
report
rate
icu
admiss
hospit
sar
mer
patient
none
report
statist
signific
result
favour
antivir
therapi
studi
report
mortal
rate
hospit
sar
mer
patient
one
cohort
studi
mer
one
retrospect
studi
sar
found
statist
signific
increas
mortal
rate
patient
treat
ribavirin
eighteen
studi
report
potenti
drugrel
advers
effect
includ
gastrointestin
symptom
anemia
alter
liver
function
patient
receiv
ribavirin
infecti
diseas
prevent
control
branch
public
health
agenc
canada
phac
submit
queri
effect
safeti
antivir
antibodi
medic
countermeasur
treatment
novel
coronaviru
canadian
institut
health
research
cihr
drug
safeti
effect
network
dsen
request
dsen
method
applic
group
indirect
comparison
magic
team
conduct
rapid
review
topic
approxim
timelin
overal
object
rapid
review
identifi
safe
effect
medic
countermeasur
address
current
outbreak
novel
coronaviru
order
focu
research
question
increas
feasibl
propos
follow
key
research
question
effect
safeti
antivir
andor
monoclon
antibodi
treatment
current
avail
treat
effect
safeti
current
avail
antivir
therapi
use
treat
coronaviru
infect
rapid
review
conduct
guid
cochran
handbook
systemat
review
intervent
along
rapid
review
guid
health
polici
system
research
team
use
integr
knowledg
translat
approach
consult
knowledg
user
public
health
agenc
canada
follow
stage
question
develop
literatur
search
studi
inclus
interpret
result
draft
report
report
submit
public
health
agenc
canada
manuscript
prepar
public
invit
knowledg
user
join
us
coauthor
use
prefer
report
item
systemat
review
metaanalys
prisma
statement
guid
report
rapid
review
result
prisma
extens
specif
rapid
review
current
develop
comprehens
literatur
search
address
research
question
research
question
develop
experienc
librarian
medlin
embas
cochran
librari
biorxivorgmedrxivorg
databas
grey
ie
difficult
locat
unpublish
literatur
locat
use
keyword
search
relev
term
eg
coronaviru
sar
etc
clinicaltrialsgov
gideon
global
infecti
diseas
epidemiolog
network
addit
final
set
includ
articl
crossreferenc
list
studi
provid
knowledg
user
public
health
agenc
health
part
scope
process
review
full
medlin
search
strategi
grey
literatur
search
keyword
found
appendix
elig
criteria
follow
picost
framework
consist
popul
research
question
individu
age
treat
coronaviru
infect
subgroup
interest
includ
older
adult
age
year
pediatr
pregnant
immunocompromis
patient
intervent
follow
intervent
elig
antivir
medic
approv
use
current
preclin
trial
anim
studi
exclud
vitro
studi
treat
see
tabl
monoclon
antibodi
approv
use
current
preclin
trial
anim
studi
exclud
vitro
studi
treat
follow
intervent
interest
antivir
agent
use
alon
combin
approv
use
coronaviru
treatment
examin
clinic
trial
use
coronaviru
treatment
tabl
compar
one
intervent
list
intervent
placebo
outcom
labconfirm
coronaviru
infect
hospit
intens
care
unit
icu
admiss
mortal
advers
event
eg
exacerb
infect
studi
publish
english
elig
inclus
due
short
timelin
review
relev
studi
written
languag
english
relev
studi
inelig
design
eg
trial
protocol
literatur
review
exclud
report
appendix
possibl
relev
articl
appendix
level
titleabstract
level
fulltext
screen
screen
form
prepar
base
elig
criteria
pilottest
review
team
use
citat
prior
level
screen
full
text
articl
prior
level
screen
agreement
review
suffici
high
case
pilottest
requir
full
screen
complet
singl
review
level
level
use
synthesisr
team
proprietari
onlin
softwar
http
breakthroughktcaloginphp
item
data
abstract
includ
studi
characterist
eg
studi
period
studi
design
countri
conduct
patient
characterist
eg
mean
age
age
rang
comorbid
intervent
detail
eg
type
intervent
dose
time
treatment
compar
detail
eg
compar
intervent
dose
outcom
result
eg
hospit
due
coronaviru
advers
event
mortal
longest
durat
followup
standard
data
abstract
form
develop
captur
data
list
item
prior
data
abstract
calibr
exercis
complet
test
form
amongst
entir
review
team
use
two
randomli
select
fulltext
articl
follow
success
complet
calibr
exercis
includ
studi
abstract
singl
review
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
risk
bia
apprais
carri
singl
review
use
cochran
risk
bia
rob
tool
control
trial
newcastl
ottawa
scale
no
cohort
casecontrol
studi
includ
studi
synthes
descript
includ
summari
statist
detail
tabl
studi
characterist
result
tabl
studi
result
organ
accord
studi
design
avail
inform
relev
subgroup
highlight
databas
search
return
total
citat
grey
literatur
search
return
citat
addit
citat
identifi
articl
provid
knowledg
user
public
health
agenc
canada
level
screen
total
citat
exclud
level
screen
citat
identifi
inelig
current
review
potenti
interest
knowledg
user
leav
potenti
relev
articl
pass
level
screen
fulltext
articl
could
obtain
time
screen
review
ad
inventori
potenti
relev
articl
articl
screen
level
pass
data
abstract
data
abstract
articl
exclud
due
lack
relev
outcom
leav
articl
includ
review
figur
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
studi
includ
review
three
control
trial
cohort
studi
seven
retrospect
medic
recorddatabas
studi
case
report
case
seri
tabl
includ
studi
publish
major
conduct
hong
kong
follow
china
saudi
arabia
canada
south
korea
taiwan
one
franc
germani
greec
unit
arab
emir
unit
state
sampl
size
studi
rang
singl
patient
case
report
group
patient
cohort
studi
overal
major
studi
dealt
treatment
sever
acut
respiratori
syndrom
sar
follow
middl
east
respiratori
syndrom
mer
two
studi
treat
unspecifi
coronaviru
major
studi
conduct
adult
popul
one
case
report
one
case
seri
includ
infant
pediatr
popul
respect
four
case
reportsseri
specif
includ
immunocompromis
patient
one
case
studi
includ
pregnant
woman
mer
howev
major
studi
popul
includ
patient
comorbid
condit
common
comorbid
includ
diabet
heart
diseas
hypertens
renal
failur
appendix
common
antivir
studi
ribavirin
follow
oseltamivir
combin
lopinavirritonavir
addit
therapi
use
studi
includ
varieti
broad
spectrum
antibiot
steroid
includ
hyrdcortison
methylprednison
prednisolon
variou
interferon
appendix
anim
human
trial
investig
monoclon
antibodi
treatment
found
rapid
review
studi
recruit
report
hospit
popul
commonli
report
outcom
mortal
follow
icu
admiss
advers
event
case
reportsseri
retrospect
studi
includ
review
assess
risk
bia
due
inher
bia
type
studi
design
trial
assess
cochran
rob
tool
cohort
studi
assess
use
no
risk
bia
includ
trial
overal
difficult
judg
due
lack
adequ
descript
studi
method
figur
three
trial
high
unclear
risk
bia
follow
compon
random
sequenc
gener
alloc
conceal
blind
participantspersonnel
appendix
cohort
studi
fair
qualiti
overal
studi
suffer
lack
repres
sampl
fail
demonstr
outcom
interest
present
start
studi
fail
adequ
ensur
compar
cohort
figur
complet
no
result
provid
appendix
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
three
studi
examin
patient
infect
includ
review
one
case
report
two
case
seri
case
report
includ
old
man
first
american
diagnos
initi
treat
vancomycin
cefepim
standard
treatment
suspect
communityacquir
pneumonia
upon
labconfirm
infect
antibiot
stop
patient
start
remdesivir
day
initi
admiss
hospit
studi
end
patient
remain
hospit
major
symptom
resolv
see
appendic
complet
detail
two
case
seri
conduct
china
includ
patient
respect
patient
hospit
initi
diagnosi
made
base
criteria
later
confirm
labtest
patient
specimen
case
seri
includ
approxim
even
number
male
femal
v
patient
rang
age
year
old
varieti
comorbid
includ
cardiovascular
diseas
chronic
kidney
liver
diseas
copd
diabet
appendix
one
case
seri
patient
treat
combin
lopinavirritonavir
arbidol
umifenovir
antibiot
shufeng
jiedu
capsul
tradit
chines
medicin
intraven
immunoglobulin
appendix
studi
end
day
two
patient
test
neg
subsequ
discharg
hospit
two
patient
remain
hospit
one
still
requir
mechan
ventil
appendix
larger
case
seri
patient
treat
oseltamivir
combin
antibiot
therapi
patient
combin
glucocorticoid
patient
appendix
cours
studi
patient
treat
oseltamivir
admit
icu
requir
invas
mechan
ventil
studi
end
day
patient
discharg
patient
die
admit
icu
appendix
four
current
ongo
random
control
trial
propos
test
treatment
identifi
keyword
search
clinicaltrialsgov
four
trial
carri
china
three
investig
antivir
medic
lopinavirritonavir
arbidol
umifenovir
darunavir
cobicstat
one
trial
investig
combin
lopinavirritonavir
tradit
chines
medicin
tcm
time
write
two
trial
start
recruit
patient
detail
tabl
youthadult
yr
labconfirm
infect
intervent
tcm
convent
medicin
compar
convent
medicin
convent
medicin
includ
oxygen
therapi
antivir
therapi
alfa
interferon
via
aerosol
inhal
lopinavirritonavir
po
bid
one
includ
trial
examin
effect
ribavirin
combin
lopinavirritonavir
compar
treatment
prophylact
measur
healthcar
worker
highli
expos
mer
unprotect
exposur
patient
pneumonia
later
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
confirm
caus
merscov
none
subject
prophylaxi
arm
ribavirinlopinavirritonavir
develop
mer
subject
control
arm
infect
mer
confirm
rptpcr
test
risk
infect
statist
significantli
lower
prophylaxi
arm
adjust
odd
ratio
ci
appendix
studi
report
outcom
one
random
trial
compar
ribavirin
supplement
hydrocortison
ribavirin
alon
three
cohort
studi
compar
oseltamivir
steroid
treatment
alon
ribavirin
continu
steroid
treatment
ribavirin
highdos
puls
steroid
ribavirin
steroid
andor
antibiot
treatment
three
retrospect
studi
examin
effect
ribavirin
oseltamivir
alon
combin
drug
case
reportsseri
examin
ribavirin
oseltamivir
lopinavirritonavir
alon
combin
steroid
antibiot
none
trial
cohort
retrospect
studi
demonstr
statist
signific
result
comparison
ie
favour
effect
ribavirin
oseltamivir
lopinavirritonavir
reduc
risk
icu
admiss
patient
sar
mer
case
report
seri
similarli
inconclus
none
studi
author
report
particular
advantag
patient
sar
mer
treat
ribavirin
oseltamivir
lopinavirritonavir
one
case
seri
includ
patient
hematolog
malign
acquir
mer
infect
patient
treat
oseltamivir
one
patient
requir
admiss
icu
due
worsen
symptom
one
case
report
pregnant
woman
mer
describ
initi
attempt
treatment
antibiot
patient
respond
transfer
icu
antivir
treatment
initi
patient
continu
deterior
die
case
seri
pediatr
patient
sar
treat
ribavirin
patient
requir
mechan
ventil
cours
ill
mortal
report
two
includ
trial
ribavirin
cohort
studi
ribavirin
lopinavirritonavir
oseltamivir
seven
retrospect
studi
ribavirin
lopinavirritonavir
oseltamivir
case
report
case
seri
ribavirin
oseltamivir
lopinavirritonavir
compar
studi
trial
cohort
fail
find
statist
signific
result
indic
none
antivir
examin
effect
reduc
mortal
sar
mer
one
cohort
studi
mer
patient
found
treatment
ribavirin
interferon
significantli
increas
mortal
risk
adjust
odd
ratio
ci
patient
cohort
gener
older
median
age
iqr
number
underli
chronic
condit
includ
diabet
cardiovascular
diseas
chronic
lung
renal
liver
diseas
malign
includ
leukemia
lymphoma
may
part
explain
increas
risk
one
retrospect
studi
sar
patient
found
mortal
rate
significantli
higher
cohort
patient
treat
ribavirin
compar
match
histor
control
ci
patient
studi
larg
middl
age
year
age
howev
larg
proport
patient
die
approxim
underli
condit
diabet
cancer
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
two
case
seri
one
case
report
includ
patient
use
remdesivir
patient
lopinavirritonavir
case
oseltamivir
case
report
death
cohort
treat
oseltamivir
four
case
reportsseri
includ
immunosuppress
patient
mer
patient
unspecifi
coronaviru
patient
report
death
patient
hematolog
malign
treat
foscarnet
oseltamivir
one
patient
hiv
patient
hematolog
malign
acquir
mer
treat
ribavirin
oseltamivir
respect
surviv
hospit
ill
day
respect
case
report
pregnant
woman
mer
treat
oseltamivir
later
ribavirin
succumb
septic
shock
day
admiss
hospit
two
case
seri
includ
pediatr
patient
treat
ribavirin
report
mortal
studi
end
one
includ
trial
seven
cohort
studi
three
retrospect
studi
seven
case
reportsseri
report
treatment
relat
advers
event
two
retrospect
studi
three
case
reportsseri
report
treatment
relat
advers
event
occur
trial
examin
effect
ribavirinlopinavirritonavir
compar
treatment
prophylact
measur
healthcar
worker
treatmentrel
advers
event
wide
report
prophylaxi
arm
includ
gi
symptom
diarrhea
nausea
stomat
anemia
leucopenia
hyperbilirubinemia
advers
effect
occur
prophylact
therapi
resolv
shortli
conclus
treatment
intervent
overal
commonli
report
advers
event
anemia
studi
alter
liver
function
studi
patient
treat
ribavirin
treatment
relat
advers
event
includ
gastrointestin
symptom
eg
nausea
vomit
chang
kidney
function
cardiac
event
eg
bradycardia
atrial
fibril
hyperglycemia
chang
mental
statu
eg
confus
anxieti
note
howev
studi
report
cardiac
advers
event
hyperglycemia
mental
statu
chang
patient
receiv
steroid
well
ribavirin
none
studi
includ
special
popul
report
treatmentrel
advers
event
public
health
agenc
canada
commiss
rapid
review
address
urgent
question
effect
safeti
antivir
antibodi
therapi
treatment
coronaviru
comprehens
literatur
search
electron
databas
grey
literatur
sourc
result
studi
variou
antivir
treatment
patient
diagnos
covid
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
sar
mer
howev
anim
human
studi
monoclon
antibodi
could
found
overal
result
includ
studi
prove
inconclus
effect
antivir
drug
treat
coronaviru
infect
prevent
particular
treatment
recommend
use
low
qualiti
avail
evid
larg
consist
case
report
case
seri
observ
studi
even
fewer
trial
howev
import
safeti
signal
identifi
includ
studi
particularli
possibl
develop
anemia
alter
liver
function
patient
receiv
ribavirin
treatment
similarli
difficult
recommend
particular
antivir
drug
promis
candid
investig
due
variabl
qualiti
inconclus
result
current
evid
review
show
howev
exist
bodi
evid
weight
heavili
toward
studi
ribavirin
shown
particular
efficaci
treat
coronaviru
may
fact
caus
harm
advers
effect
futur
investig
potenti
antivir
therapi
coronaviru
may
best
serv
point
attent
drug
candid
sever
limit
review
method
employ
singl
screen
abstract
exampl
howev
select
thought
tailor
method
accord
knowledg
user
need
urgent
natur
request
provid
time
result
current
evid
effect
antivir
therapi
coronaviru
conclus
suffer
lack
welldesign
prospect
trial
observ
studi
none
intervent
examin
review
recommend
use
patient
coronaviru
similarli
firm
recommend
made
intervent
safeti
perspect
due
lack
conclus
evid
import
safeti
signal
potenti
relat
ribavirin
use
identifi
anemia
alter
liver
function
also
requir
investig
clarifi
relat
drug
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
protocol
multicentr
doubl
blind
randomis
placebocontrol
trial
efficaci
safeti
lopinavirritonavir
plu
ribavirin
treatment
sever
acut
respiratori
syndrom
recoveri
sever
novel
coronaviru
infect
mer
unavail
ribavirin
primari
prevent
treatment
middl
east
respiratori
syndrom
coronaviru
preliminari
report
two
case
